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Background: Inﬂuenza results in up to 500,000 deaths annually. Seasonal inﬂuenza vaccines have an
estimated 60% effectiveness, but provide little or no protection against novel subtypes, and may be less
protective in high-risk groups. Neuraminidase inhibitors are recommended for the treatment of severe
inﬂuenza infection, but are not proven to reduce mortality in severe disease. Preclinical models of severe
inﬂuenza infection that closely correlate to human disease are needed to assess efﬁcacy of new vaccines
and therapeutics.
Methods: We developed a nonhuman primate model of inﬂuenza and bacterial co-infection that re-
capitulates severe pneumonia in humans. Animals were infected with inﬂuenza A virus via intra-
bronchial or small-particle aerosol inoculation, methicillin-resistant Staphylococcus aureus, or co-
infected with inﬂuenza and methicillin-resistant S. aureus combined. We assessed the severity of dis-
ease in animals over the course of our study using tools available to evaluate critically ill human patients
including high-resolution computed tomography imaging of the lungs, arterial blood gas analyses, and
bronchoalveolar lavage.
Results: Using an intra-bronchial route of inoculation we successfully induced severe pneumonia
following inﬂuenza infection alone and following inﬂuenza and bacterial co-infection. Peak illness was
observed at day 6 post-inﬂuenza infection, manifested by bilateral pulmonary inﬁltrates and hypoxemia.
The timing of radiographic and physiologic manifestations of disease in our model closely match those
observed in severe human inﬂuenza infection.
Discussion: This was the ﬁrst nonhuman primate study of inﬂuenza and bacterial co-infection where
high-resolution computed tomography scanning of the lungs was used to quantitatively assess pneu-
monia over the course of illness and where hypoxemia was correlated with pneumonia severity. With
additional validation this model may serve as a pathway for regulatory approval of vaccines and ther-
apeutics for the prevention and treatment of severe inﬂuenza pneumonia.
Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).artment, Clinical Center, NIH,
1662, USA.
w).
access article under the CC BY-NC1. Introduction
An estimated 5e10% of adults and 20e30% of children are
infected with inﬂuenza globally each year. Severe illness occurs
predominantly in high-risk groups (the very young, elderly, and
those with premorbid conditions) affecting an estimated 3e5
million people resulting in an estimated 250,000e500,000 deaths-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Back-titration results for inﬂuenza and bacterial challenge inoculum.
Experimental group Delivered inoculum (mean ± standard deviation)
Sw31 (PFU/animal) MRSA (CFU/animal)
1: Saline X X
2: MRSA X 1.20  109 ± 4.00  108
3: Sw31 IB 2.06  106 ± 1.30  106 X
4: Sw31 IB þ MRSA 2.11  106 ± 3.15  105 1.33  109 ± 3.8  108
5: Sw31 aero 6.15  106 ± 4.86  105 X
6: Sw31 aero þ MRSA 6.21  106 ± 3.85  106 8.88  108 ± 1.25  108
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pandemic caused an estimated 50 million deaths worldwide,
disproportionately affecting young adults (World Health
Organization, 2015). Zoonotic avian inﬂuenza (e.g., H5N1 and
H7N9) causes infrequent although highly lethal human infections
and poses risk for a severe pandemic (Su et al., 2015).
Seasonal inﬂuenza vaccines have an estimated 60% effective-
ness, but provide little or no protection against novel inﬂuenza
subtypes, and may be less protective in high-risk groups. Neur-
aminidase inhibitors (NAIs) are recommended for the treatment of
severe inﬂuenza infection, but are not proven to reducemortality in
severe disease. Recent meta-analysis of observational data suggest
early initiation of NAI therapy, within 5-days of symptom onset, is
associated with reduced mortality (Muthuri et al., 2014). However,
patients with severe inﬂuenza infection typically present to the
hospital after 5-days of symptoms and experience high case-
fatality (Rice et al., 2012).
New vaccines and therapies are needed to prevent and treat
severe inﬂuenza illness. Efﬁcacy of interventions must be assessed
accounting for the impact of bacterial co-infection that commonly
contributes to mortality (Morens et al., 2008). Clinical trials of
inﬂuenza vaccine or therapeutic efﬁcacy do not typically evaluate
severe disease as a clinical endpoint, largely due to the expense
required to adequately power such studies. Highly pathogenic
strains of inﬂuenza and severe disease cannot be assessed in human
challenge experiments for obvious ethical reasons. Preclinical
models of severe inﬂuenza infection that closely correlate with the
natural history of disease in humans are needed to assess efﬁcacy of
vaccines and therapeutics. Showing beneﬁt of interventions in
permissive small animals (mice and ferrets) that are genetically and
phenotypically distinct from humans may not adequately translate
to beneﬁt in humans.
Nonhuman primates are naturally, and may be experimentally,
infected with human inﬂuenza viruses (Davis et al., 2015). Seasonal
inﬂuenza infection in most nonhuman primate species results in
mild or subclinical illness, reﬂective of self-limited disease
observed in otherwise healthy humans. Inoculation of inﬂuenza
into the lower airways of nonhuman primates induces more severe
disease than upper airway inoculation or exposure via small par-
ticle aerosol (Davis et al., 2015). Bacterial infection following intra-
tracheal inﬂuenza infection has been evaluated in four nonhuman
primate studies since 1954 (Berendt, 1974; Berendt et al., 1975;
Kobayashi et al., 2013; Miyake et al., 2010). In three of the four
studies co-infection resulted in more severe bronchopneumonia
than viral infection alone.
We sought to develop a nonhuman primate model of inﬂuenza
and bacterial co-infection that recapitulates severe disease in
humans. Severe inﬂuenza infection in humans is typically man-
ifested by bilateral bronchopneumonia resulting in hypoxemia.
Animals were infected with inﬂuenza inoculated directly into
bilateral main-stem bronchi, to maximize lower respiratory tract
disease. Decades of experimental observations show that intra-
nasal inoculation induces only mild illness in both otherwise
healthy nonhuman primate and human subjects. Co-infected ani-
mals were inoculated with bacteria into the lower airways at four
days post-inﬂuenza infection. The timing of co-infection in our
study closely approximates estimated timing of co-infection in
human cases of severe inﬂuenza infection (Rice et al., 2012).
Inﬂuenza A/Swine/Iowa/31 (Sw31) was selected as a surrogate for
the 1918 pandemic inﬂuenza virus in this study based on close
genetic homology and similar pathogenesis in mice and ferrets
(Memoli et al., 2009). Methicillin-resistant Staphylococcus aureus
(MRSA) was selected as a clinically relevant bacterial co-pathogen.
We also evaluated the role of aerosolized inﬂuenza with and
without bacterial co-infection in this study. Few historical dataexist to inform the impact of aerosolized inﬂuenza on the devel-
opment of severe pneumonia in the setting of bacterial co-
infection. We sought to ﬁll this knowledge gap. We assessed the
severity of disease in animals over the course of our study using
tools available to evaluate critically ill human patients. These
included high-resolution computed tomography (CT) imaging of
the lungs, arterial blood gas analyses, and bronchoalveolar lavage
(BAL).
2. Methods
2.1. Inoculations
Eighteen male juvenile rhesus macaques (4e8 kg) of Indian
origin without detectable pre-existing inﬂuenza A antibody titers
were randomly assigned to one of six study groups (see Table,
Supplementary Table 1). Staff that assigned animals to groups were
blinded to the intervention (i.e., pathogen and inoculation route)
designated for that group. Viral stocks of Inﬂuenza A/Swine/Iowa/
31 (Sw31) were grown in MadineDarby canine kidney (MDCK)
cells, harvested, puriﬁed on a sucrose cushion, and stored at80 C.
Viral titers were assessed by plaque assay technique (Qi et al.,
2009). MRSA (strain USA300) was grown in tryptic soy broth
(TSB) from frozen glycerol stocks until mid-log phase growth was
achieved. The desired number of bacteria were pelleted, washed,
and diluted in 4 mL of sterile saline immediately prior to inocula-
tion. Bacterial titers were conﬁrmed by serial dilution of samples on
TSB agar plates Table 1.
Intra-bronchial (IB) inoculations were performed under keta-
mine anesthesia using a pediatric bronchoscope advanced into the
airway of seated upright animals (see experimental timeline, Fig.1).
A target IB viral inoculum of 5 106 plaque forming units (pfu) was
diluted in 4 mL of saline and administered in equal proportions into
the right and left main stem bronchus. A target IB bacterial inoc-
ulum of 1  109 colony forming units (cfu) was similarly adminis-
tered. A target aerosol viral inoculum of 5  106 pfu was
administered as previously described (Johnson et al., 2015). All
animal procedures were approved by the National Institute of Al-
lergy and Infectious Diseases (NIAID) Division of Clinical Research
Animal Care and Use Committee, and adhered to National Institutes
of Health (NIH) policies. The experiments were carried out at the
NIAID Integrated Research Facility, an AAALAC and AALAS
accredited facility.
2.2. Procedures
Physical exams, vital sign measurements, and venous and
arterial blood draws were performed every other day and BALs
were performed every fourth day under ketamine anesthesia.
Arterial blood was collected by puncture of the femoral artery
under direct ultrasound guidance at atmospheric pressure and
samples were immediately loaded onto the iSTAT® (Abbott labo-
ratories) for bedside blood gas analysis. BALs were performed by
Fig. 1. Study timeline and viral RNA copy number in bronchoalveolar lavage. A) Inoculation schedule. B) Viral RNA copy number in bronchoalveolar lavage from inﬂuenza
inoculated groups. Data are represented as box plots showing median values (bar) and range (box). Comparison between groups was assessed by two-way ANOVA and signiﬁcance
testing by Tukey's test, *p < 0.05.
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of an upright animal, instilling four 10 mL aliquots (40 mL total) of
sterile saline into the distal lung segment, and aspirating BAL ﬂuid
into a sterile trap.
2.3. Laboratory testing
Complete blood counts (CBC) with differentials and compre-
hensive blood chemistries were performed on venous blood sam-
ples collected in ethylenediaminetetraacetic acid (EDTA)-coated
blood tubes using a Sysmex XT2000V™ (Sysmex America, IL USA)
and the Piccolo Xpress® (Abbott laboratories).
Quantitative real-time PCR (RT-PCR) was used to determine the
viral copy numbers in BAL samples from all groups. Total RNA was
extracted from 100 mL aliquots of BAL using standard TRIzol chlo-
roform extraction. Reverse transcription of total RNA was per-
formed with primers speciﬁc for swine H1N1 HA sequence using
the Superscript III ﬁrst-strand cDNA synthesis kit (Invitrogen,
Carlsbad, CA). TaqMan primers and probes were designed using
Primer Express 3.0 software (Applied Biosystems, Foster City, CA)
and generated the following primers and probe: Swine-691F, 50
CAGGAGGTTCACTCCAGAAATAG 30; Swine-787R, 50
GTGTCTCCGGGTTCTAGTAATG 30; Probe, 50 FAM-
AGGTCAGGCAGGGAGGATGAACTA-TAMRA 30. RT-PCR was per-
formed on an Applied Biosystems QuantStudio 6 Flex Real-Time
PCR System and each sample was run in duplicate with TaqMan
2X PCRUniversal MasterMix (Applied Biosystems) and a 25 mL total
reaction volume. Quantiﬁcation of viral copy number was accom-
plished by comparison of RT-PCR results to an established external
standard of viral copy number.
Cells from BAL were pelleted by centrifugation and re-
suspended in 100 ml phosphate buffered saline (PBS) þ 2% fetal
bovine serum (FBS). Cell aliquots were exposed to a myeloid or
lymphoid antibody panel. Themyeloid panel containedmarkers for
CD14, Live/Dead Fixable Yellow dead cell stain (Thermo Fisher
Scientiﬁc, MA, USA), CD3, CD45, HLA-DR, CD11c (BD Biosciences,CA, USA), CD20 (eBioscience Inc. CA, USA), CD66abce (Miltenyi
Biotech Inc. CA, USA), and CD163 (Biolegend, CA, USA). The
lymphoid panel contained markers for CD3, CD8, CD20, CD16 (BD
Biosciences, CA, USA), CD4 (Biolegend, CA, USA), CD14, Live/Dead
Fixable Yellow dead cell stain (Thermo Fisher Scientiﬁc, MA, USA)
and CD 159(NKG2a) (Beckman Coulter, CA, USA). Samples were
then ﬁxed and permeabilized using BD Cytoﬁx/Cytoperm solution
(BD Biosciences CA, USA) and analyzed on the BD LSR II Fortessa
Flow Cytometer. Datawere analyzed using FlowJo Software (FlowJo
LLC, OR, USA). All cells were gated ﬁrst as live cells (viability dye
negative) and CD45þ and then analyzed further. Myeloid cells were
gated by forward and side scatter and monocytes were deﬁned as
CD3CD20HLA-DRþCD163þ. CD3CD20CD163 cells were
separated by CD66abceþ (neutrophils) or CD11cþ (dendritic cells).
Lymphoid cells were gated by forward and side scatter and CD14.
B cells were deﬁned as CD3CD20þ and NK cells were deﬁned as
CD3NKG2aþ. T cells were deﬁned as CD20 and CD4þCD8 or
CD4CD8þ. Percentage of each cell type was determined based on
all live CD45þ cells.
2.4. High-resolution computed tomography scanning
Animal were intubated, deeply sedated with propofol, and
mechanically ventilated on an assist-control volume-cycled venti-
lator mode. A standard breath-hold maneuver normalizing tidal
volume to 8 cc/kg actual body weight was performed immediately
prior to CT imaging of lungs using a Philips Gemini 16 slice PET/CT
scanner. Lung hyper-intensity and percent change from baseline
over time was determined using previously published methods
(Solomon et al., 2014).
2.5. Pathology
Detailed necropsies were performed on all animals following
euthanasia. Tissues were collected from major organs including
multiple lung lobes, preserved in 10% normal-buffered formalin,
Fig. 2. High resolution computed tomography imaging of lungs; percent change in lung hyper-intensity over time; and animals that met clinical criteria for acute lung
injury. A) Representative sagittal lung images of animals from each group over time. B) Percent change in lung hyper-intensity for all animals in each group over time. Bar graphs
represent groupmeans and SEMs. Comparison between groups was assessed by two-way ANOVA and signiﬁcance testing by Tukey's test, *p < 0.05, **p < 0.01, and ****p < 0.0001. C)
Animals (individuals dots) that met clinical criteria acute lung injury including arterial partial pressure of oxygen to fraction of inspired oxygen (P:F) ratio < 300 (below dotted line)
and bilateral radiographic inﬁltrates.
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charged slides for hematoxylin and eosin staining. Lung lobes were
sampled for a qualitative assessment of histopathology. Both
“affected” and “unaffected” regions, based upon gross pathologic
evaluation, were sampled.
2.6. Statistical analysis
GraphPad Prism 6 was used for all statistical analysis including
mean and standard error of the mean (SEM) calculations. Two-way
ANOVA was used to detect differences in dependent variables be-
tween groups on multiple study days. Tukey's test was used to
assess for signiﬁcant differences between means with p < 0.05,
p < 0.01, p < 0.001, or p < 0.0001.3. Results
3.1. Inﬂuenza and MRSA infection induced mild clinical or
subclinical illness
Animals were inoculated with Sw31 or saline on day 0 and
MRSA or saline on day þ4 (Fig. 1). Viral and bacterial inoculation
doses were conﬁrmed by back-titration (Table). Group 3 (Sw31 IB)
animals had the highest peak viral RNA in lung-lining ﬂuid at
day þ2 that signiﬁcantly declined by day þ6 (Fig. 1). MRSA was
cultured from lung-lining ﬂuid of all 3 animals from Group 4 (Sw31
IB þ MRSA) on day þ6 but not at later time-points and not from
animals in other MRSA-infected groups (Groups 2 and 6).
Clinical scoring to quantify disease severity and early euthanasia
Fig. 3. Total CD45þ cells in bronchoalveolar lavage by group over time. Bar graphs represent group means and SEMs. Comparison between groups was assessed by two-way
ANOVA and signiﬁcance testing by Tukey's test, *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.
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in groups 3 (Sw31 IB), 4 (Sw31 IB þ MRSA), and 6 (Sw31
aero þMRSA) developed self-limited fever to greater >39.7 C. One
animal each from Groups 3 and 4 developed mild cough on day þ6
and þ7 and two animals from Group 4 developed mild depressed
activity on day þ6. Less than 5% weight loss was observed in all
animals. No clinically signiﬁcant abnormalities were observed in
CBC with differentials or serum chemistries.
3.2. CT imagining of lungs characterized timing and extent of
inﬂuenza or MRSA pneumonia
Radiographic evidence of pneumonia with focal or multifocal
inﬁltrates was observed in all infected animals in Groups 2 (MRSA),
3 (Sw31 IB), 4 (Sw31 IBþMRSA), and 6 (Sw31 aeroþMRSA) but not
in animals from Groups 1 (saline IB) or 5 (Sw31 aero) (Fig. 2A). No
statistically signiﬁcant difference was observed in density of
radiographic inﬁltrates on day þ2, as measured by percent change
in lung hyper-intensity (PCLH) between groups (Fig. 2B). On dayþ6,
PCLH was signiﬁcantly increased in Group 4 animals (Sw31
IB þ MRSA) relative to animals in all other groups, and in group 3
(Sw31 IB) and 6 (Sw31 aero þMRSA) animals relative to animals in
Groups 1 (saline) and 5 (Sw31 aero) (Fig. 2B). On dayþ10, PCLHwas
signiﬁcantly increased in Group 4 animals (SW31 IB þ MRSA)
relative to animals in Groups 1 (saline), 2 (MRSA), and 5 (Sw31
aero) (Fig. 2B). No statistically signiﬁcant differences in PCLH were
observed between groups on day þ14 (Fig. 2B).
3.3. IB inﬂuenza with or without MRSA co-infection induced acute
lung injury by clinical criteria
The clinical criteria for acute lung injury (ALI) include an arterial
partial pressure of oxygen to fraction of inspired oxygen (P: F) ratio
<300 in the setting of bilateral pulmonary inﬁltrates (Bernard et al.,
1994). Three animals fromGroup 3 (Sw31 IB) and two animals from
Group 4 (Sw31 IB þ MRSA) met clinical criteria for ALI on day þ6(Fig. 2C). Clinical criteria for ALI were not met on other study days
or in other groups. Timing of ALI in animals from Groups 3 and 4
correlated with timing of peak radiographic inﬁltrates (Fig. 2B and
C).
3.4. Cellular immune responses in BAL were distinct between
groups
Animals from Group 1 (saline) had no signiﬁcant changes in the
number or distribution of immune cell populations in BAL (Figs. 3
and 4 A-G) over the course of the study. Group 2 (MRSA) animals
had signiﬁcant elevations of NK cells (CD14CD3NKG2Aþ), den-
dritic cells (CD3CD20CD163CD66HLA-DRþ/CD11cþ), neutro-
phils (CD3CD20CD163CD11cCD66þ), monocytes
(CD3CD20HLA-DRþCD163þ), and B-cells (CD14CD3CD20þ)
(Fig. 4A, C, D, E, and G) on day þ6 and all cell populations returned
to baseline by day þ10. Group 3 (Sw31 IB) animals showed signif-
icant elevation of neutrophils on day þ6 (Fig. 4D) and cytotoxic T-
cells (CD14CD20 CD3þCD4CD8þ) and dendritic cells on dayþ14
(Fig. 4 B and C). Group 4 (Sw31 IB þMRSA) animals had signiﬁcant
elevations of neutrophils, monocytes, and B-cells on day þ6
(Fig. 4D, E, and G) and signiﬁcant elevations of cytotoxic T-cells and
dendritic cells on day þ10 (Fig. 4B and C). CD4þ T-cell populations
(CD14CD20 CD3þCD8CD4þ) were signiﬁcantly elevated on
day þ6 and þ10 (Fig. 4F). Group 5 (SW31 aero) animals had sig-
niﬁcant elevation in NK cells on day þ6 (Fig. 4A). Group 6 (Sw31
aero þ MRSA) animals had signiﬁcant elevations of NK cells on
days þ2, þ6, and þ10 (Fig. 4A); of neutrophils on days þ2 and þ6
(Fig. 4D); of monocytes on days þ6 and þ10 (Fig. 4E); of B-cells on
day þ6 (Fig. 4G); and of cytotoxic T-cells, dendritic cells, and CD4þ
T-cells on day þ10 (Fig. 4B, C, and F).
3.5. Pneumonia and pathologic lung injury were most severe
following IB inﬂuenza and MRSA co-infection
Histopathologic examinationwas performed on tissues sampled
Fig. 4. Immunophenotypes of CD45þ cells from bronchoalveolar lavage by group over time. A) NK cells; B) Cytotoxic T-cells; C) Dendritic cells; D) Neutrophils; E) Monocytes; F)
CD4þ cells; G) B-cells. Bar graphs represent group means and SEMs. Comparison between groups was assessed by two-way ANOVA and signiﬁcance testing by Tukey's test,
*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.
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thology in the respiratory epithelium of the trachea, main-stembronchi (Fig. 5A), bronchioles (Fig. 5B), or lung parenchyma
(Fig. 5C). Group 2 (MRSA) animals had focal chronic bronchiolitis
Fig. 5. Dayþ14 histopathology of lungs from Sw31 and/or MRSA infected animals (Groups 1 to 3). AeC) Group 1 saline: No signiﬁcant histopathological changes were noted in
the tracheobronchial tree (A & B) or in the lung parenchyma (C); DeF) Group 2 MRSA: sections demonstrated foci of chronic bronchiolitis (D) with evidence of repair (E), and rare,
foci of luminal bacteria (F, arrow); GeL) Group 3 Sw31 IB: sections showed multifocal areas of acute DAD (G) with alveolar edema and capillary congestion (H) admixed with
multifocal areas of organizing DAD with interstitial ﬁbrosis (I, arrow) and type II alveolar hyperplasia (J, arrow), focal chronic bronchiolitis (K, arrow), and focal bronchiolitis
obliterans (L, arrow). Original magniﬁcations are as follows: (A) 20, (B) 100, (C) 20, (D) 400), (E) 100, (F) 400, (G) 40, (H) 200, (I) 200, (J) 400, (K) 40, (L) 100.
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with bacteria morphologically consistent with Staphylococcus
associated with small amounts of necrotic luminal debris (Fig. 5F;
arrow). Group 3 (Sw31 IB) animals had few foci of acute exudative
DAD (Fig. 5G; left half) characterized by prominent alveolar edema
and vascular congestion (Fig. 5H), surrounded bymultifocal areas of
proliferative organizing DAD (Fig. 5G; right half) characterized by
interstitial ﬁbrosis (Fig. 5I; arrow) and type II alveolar cell hyper-
plasia (Fig. 5J; arrow). Multifocal chronic bronchiolitis was also
observed (Fig. 5K; arrow) with several foci of bronchiolitis oblit-
erans (Fig. 5L, arrow). Group 4 (Sw31 IB þ MRSA) animals had
extensive pathology with widespread consolidation in most lung
lobes. Organizing pneumonia with extensive organizing DAD
(Fig. 6AeC), with multifocal bronchiolitis obliterans (Fig. 6AeC ar-
rows), chronic bronchiolitis with transmural inﬁltrates of inﬂam-
matory cells and loss of epithelial cell integrity (Fig. 6D) were
observed. The key features of the areas of organizing DAD included
interstitial ﬁbrosis (Fig. 6E; arrows) and type II alveolar cell hy-
perplasia (Fig. 6F; arrow). Group 5 (Sw31 aerosol) (Fig. 6GeI) and 6
(Sw31 aeroþMRSA) (Fig. 6JeL) animals had similar histopathology
features with multifocal areas of interstitial inﬂammatory in-
ﬁltrates producing an interstitial pneumonia pattern (Fig. 6G and J)
with multifocal areas of chronic bronchiolitis oftenwith prominentsubmucosal lymphoid nodules (Fig. 6H & KL; arrows). Areas with
organizing DAD features were noted (Fig. 6I) with interstitial
ﬁbrosis and type II hyperplasia (Fig. 6L) but were much less
prominent than observed in groups 3 and 4.
4. Discussion
We developed amodel of severe pneumonia following inﬂuenza
and bacterial co-infection in nonhuman primates. This was the ﬁrst
nonhuman primate study of inﬂuenza and bacterial co-infection
where high-resolution CT scanning of the lungs was used to
quantitatively assess pneumonia over the course of illness and
where hypoxemia was correlated with pneumonia severity. This
was also the ﬁrst nonhuman primate study of inﬂuenza and bac-
terial co-infection where immune cell responses in BAL were seri-
ally evaluated in animals over the course of illness. Using an IB
route of inoculation we successfully induced severe pneumonia
following inﬂuenza infection alone and following inﬂuenza and
bacterial co-infection. Peak illness was observed at day 6 post-
inﬂuenza infection, manifested by bilateral pulmonary inﬁltrates
and hypoxemia. The timing of radiographic and physiologic mani-
festations of disease in our model closely match those observed in
severe human inﬂuenza infection (Chertow, 2012).
Fig. 6. Day þ14 histopathology of lungs from Sw31 and/or MRSA infected animals (Groups 4 to 6). AeF) Group 4 Sw31 IB þ MRSA: multifocal areas of organizing pneumonia
(AeC) with acute DAD with alveolar edema and capillary congestion admixed focal chronic bronchiolitis (D) and bronchiolitis obliterans (AeC, arrows), with multifocal areas of
organizing DAD with interstitial ﬁbrosis (E, arrows) and type II alveolar hyperplasia (F, arrow); GeI) Group 5 Sw31 aero: multifocal areas of interstitial pneumonia (G), focal chronic
bronchiolitis with prominent submucosal lymphoid nodules (H, arrow), and multifocal areas of organizing DAD (I); JeL) Group 6 Sw31 aero þMRSA: multifocal areas of interstitial
pneumonia (J), focal chronic bronchiolitis with prominent submucosal lymphoid nodules (K, arrow), and multifocal areas of organizing DAD, with interstitial ﬁbrosis and type II
aveolar hyperplasia (L). Original magniﬁcations are as follows: (A) 40, (B) 40, (C) 40, (D) 100), (E) 200, (F) 400, (G) 40, (H) 40, (I) 200, (J) 40, (K) 40, (L) 200.
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in more severe lung histopathology than inﬂuenza infection alone.
This same observation has been made in three of four prior
nonhuman primate studies of inﬂuenza and bacterial co-infection
where inﬂuenza was inoculated into the lower airways (Berendt,
1974; Berendt et al., 1975; Kobayashi et al., 2013; Miyake et al.,
2010). In the most recent study by Kobayashi et al., no difference
in lung histopathology was observed following inﬂuenza infection
alone versus inﬂuenza and bacterial co-infection (Kobayashi et al.,
2013). However, the MRSA inoculating dose employed by these
authors was 1  106 CFU, 3 logs lower than the dose used in our
study and lung histopathology was assessed at day 9 post-inﬂuenza
infection, likely past the peak of illness.
Pneumonia in our model did not progress to refractory hypoxic
respiratory failure or death. We postulate that the underlying
normal health status of the animals protected them from more
severe disease, similar to most healthy humans infected with
inﬂuenza. A recent inﬂuenza A challenge study in humans
showed that a dose of 107 tissue culture infectious dose 50 was
needed to induce mild illness in 69% of individuals (Memoli et al.,
2015). These data suggest that high-dose inﬂuenza A exposure is
likely needed to induce more than mild illness in healthy hosts.Despite this, development of pneumonia was reproducible in our
model. Severity of inﬂuenza pneumonia is dependent upon the
viral and bacterial strain used, pathogen dose, and route of
infection. We selected Sw31 because it is well characterized in
mice and ferrets to cause severe pneumonia, and is genetically
similar to 1918 inﬂuenza, that causes severe pneumonia in
nonhuman primates (Kobasa et al., 2007). Viral dose of
5  106 pfu was selected as the highest dose that could be
reasonably achieved and matched across routes of delivery. MRSA
was selected given its high prevalence among adult and pediatric
patients with severe inﬂuenza infection (Rice et al., 2012;
Randolph et al., 2011). While MRSA is known to induce pneu-
monia in nonhuman primates, Panton-Valentine leukocidin (PVL)
does not appear to signiﬁcantly contribute to pathogenesis (Olsen
et al., 2010). While PVL is known to be a S. aureus virulence
molecule in vitro, its contribution to pneumonia pathogenesis in
humans remains controversial. While the route of infection we
studied does not mirror natural infection, our intention was not to
evaluate the natural history of mild inﬂuenza infection. This can
be best accomplished in human challenge experiments or natural
history studies. Our intention was to model severe inﬂuenza
pneumonia as observed in humans.
D.S. Chertow et al. / Antiviral Research 129 (2016) 120e129128To expand the relevance of our ﬁndings and establish the utility
of this model for assessing efﬁcacy of vaccines and therapies for the
prevention and treatment of severe inﬂuenza pneumonia, addi-
tional experiments are needed. Future studies should assess
reproducibility of our ﬁndings with other relevant seasonal and
high-path avian inﬂuenza strains with pandemic potential. Strep-
tococcus pneumonia, another clinically relevant bacterial co-
pathogen, should also be evaluated. Dose response studies are
also needed. Quantitative assessment of lung histopathology
correlated to CT ﬁndings at peak illness (day 6) will also strengthen
the validity of this model. Interestingly aerosolized inﬂuenza alone
induced only subclinical disease despite presence of interstitial
pneumonia on lung histopathology. This was made only moder-
ately worse with bacterial co-infection. Some variation in delivered
inoculum was observed, primarily across routes of delivery. This is
likely attributable to methodological differences required to deliver
virus IB versus aerosol. Also, the design of the aerosol chamber,
where not all inoculum is delivered into the airway, likely resulted
in a dose reduction in the inﬂuenza aerosol groups. However,
diffuse interstitial pneumonia observed on histopathology in these
groups, and robust immune response in BAL suggest that aerosol
exposure to inﬂuenza results in a distinct and more mild clinico-
pathological phenotype.
Nonhuman primate models of inﬂuenza infection will not and
should not replace mice and ferret studies for the preclinical
assessment of inﬂuenza vaccines and therapies. Relevant small
animal models will always be needed for initial higher throughput
evaluation of interventions. However, nonhuman primate models
provide an important adjunct for validating ﬁndings in small ani-
mal models and may more closely predict vaccine and therapeutic
efﬁcacy for severe disease in humans. Lung immune cell responses
in nonhuman primates likely correlate better to those of humans
than those of more genetically distant animals. Characterization of
lung immune cell responses in nonhuman primates following
inﬂuenza infection may facilitate discovery of improved correlates
of inﬂuenza immunity in humans, needed for better vaccine design.
Additionally, characterization of lung immune responses contrib-
uting to progression and resolution of lung injury may lead to
discovery of novel therapeutic targets within the host to improve
severe pneumonia outcomes.
In summary, we report a nonhuman primate model of IB
inﬂuenza and MRSA co-infection that induced severe pneumonia
similar to that observed in humans. With additional validation this
model may serve as a pathway for regulatory approval of vaccines
and therapeutics for the prevention and treatment of severe
inﬂuenza pneumonia. This will be particularly useful for high-path
avian inﬂuenza strains with pandemic potential that cause sporadic
infections and are thus not easily amenable to large clinical trials of
vaccine and therapeutic efﬁcacy.
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